QRG Capital Management Inc. Has $21.73 Million Stake in Pfizer Inc. $PFE

Key Points

• QRG Capital Management increased its Pfizer stake by 5.8% in the second quarter, owning 902,308 shares valued at approximately $21.73 million. Institutional investors collectively own 68.36% of Pfizer.
• Pfizer reported quarterly earnings of $0.77 per share, beating estimates of $0.68, while revenue rose 2.6% year over year to $15.03 billion. The company maintained 2026 adjusted EPS guidance of $2.80–$3.00.
• Analyst sentiment remains cautious, with Pfizer carrying a consensus “Hold” rating and an average price target of $28.39. Investors are weighing pipeline-driven growth and the roughly 6% dividend yield against declining COVID-product sales and potential payout risks.

QRG Capital Management Inc. lifted its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 5.8% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 902,308 shares of the biopharmaceutical company's stock after buying an additional 49,804 shares during the period. QRG Capital Management Inc.'s holdings in Pfizer were worth $21,728,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Envestnet Portfolio Solutions Inc. lifted its stake in Pfizer by 16.0% during the second quarter. Envestnet Portfolio Solutions Inc. now owns 179,745 shares of the biopharmaceutical company's stock worth $4,328,000 after purchasing an additional 24,744 shares during the last quarter. Envestnet Asset Management Inc. increased its stake in shares of Pfizer by 1.8% in the 2nd quarter. Envestnet Asset Management Inc. now owns 9,513,242 shares of the biopharmaceutical company's stock valued at $229,078,000 after purchasing an additional 167,641 shares during the last quarter. Andra AP fonden lifted its position in shares of Pfizer by 196.6% during the 2nd quarter. Andra AP fonden now owns 728,273 shares of the biopharmaceutical company's stock worth $17,537,000 after buying an additional 482,700 shares during the last quarter. State Street Corp lifted its position in shares of Pfizer by 1.8% during the 2nd quarter. State Street Corp now owns 307,090,897 shares of the biopharmaceutical company's stock worth $7,394,749,000 after buying an additional 5,501,032 shares during the last quarter. Finally, Security National Bank of Sioux City Iowa IA bought a new position in Pfizer in the second quarter valued at about $76,000. Institutional investors own 68.36% of the company's stock.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: An optimistic investment case argues that Pfizer’s next phase of growth could come from a smaller, faster-growing portion of the business rather than its established COVID products or additional cost reductions. This supports the possibility of revenue diversification as COVID sales continue to shrink. What Is The Best Case For Pfizer Stock?
• Positive Sentiment: A recent bullish view highlighted Pfizer’s pipeline and suggested the shares could be undervalued if new products and post-loss-of-exclusivity opportunities improve the company’s growth profile. Its roughly 6% yield also remains attractive to income-focused investors. Pfizer: A Quietly Outperforming High-Dividend Idea, Pipeline On Watch (Upgrade)
• Neutral Sentiment: Pfizer will host a webcast and analyst conference call on November 3, giving investors a forthcoming opportunity to assess guidance, pipeline progress and capital-allocation plans. CEO Albert Bourla’s planned attendance at a White House dinner with China’s president may also keep attention on the company’s international relationships, although no business impact was announced. Pfizer Invites Public to View and Listen to Webcast
• Negative Sentiment: Several articles cautioned that Pfizer’s high yield may not be as secure as it appears. Although the company generates positive free cash flow, elevated payout ratios and limited dividend growth could restrict flexibility and increase the risk of a future payout reduction. Pfizer, Kraft, and UPS All Yield More Than 6%
• Negative Sentiment: Bearish commentary said revenue has been broadly flat while COVID products decline and questioned whether the shares already reflect the benefit of a recent overseas pricing agreement. Other comparisons favored faster-growing rivals such as Eli Lilly, while one analyst view downgraded Pfizer to Hold until longer-term growth becomes more visible. Pfizer Stock May Be Overvalued After Overseas Pricing Deal

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on PFE shares. Cantor Fitzgerald reissued a "neutral" rating and issued a $27.00 target price on shares of Pfizer in a report on Monday, July 6th. Bank of America lowered their price objective on shares of Pfizer from $27.00 to $26.00 and set a "neutral" rating for the company in a research report on Friday, July 10th. JPMorgan Chase & Co. cut their target price on shares of Pfizer from $30.00 to $28.00 and set a "neutral" rating on the stock in a research report on Wednesday, July 8th. Guggenheim lowered their price target on shares of Pfizer from $35.00 to $31.00 and set a "buy" rating for the company in a report on Friday, August 7th. Finally, HSBC increased their price target on Pfizer from $28.00 to $30.00 and gave the company a "hold" rating in a research note on Thursday, September 10th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Pfizer presently has a consensus rating of "Hold" and an average target price of $28.39.

Pfizer Stock Up 0.8%

Shares of NYSE:PFE opened at $28.16 on Thursday. The firm has a market cap of $160.52 billion, a P/E ratio of 37.06, a P/E/G ratio of 1.88 and a beta of 0.34. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71. Pfizer Inc. has a 12-month low of $23.58 and a 12-month high of $29.21. The business has a fifty day simple moving average of $26.91 and a 200 day simple moving average of $26.40.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, beating analysts' consensus estimates of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The firm had revenue of $15.03 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same quarter in the previous year, the company posted $0.78 EPS. The business's revenue was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Analysts predict that Pfizer Inc. will post 2.98 earnings per share for the current year.

Pfizer Company Profile

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its portfolio addresses a range of therapeutic areas, including oncology, inflammation and immunology, internal medicine, hospital care, rare diseases and infectious diseases. The company serves patients and healthcare providers in markets worldwide.

Pfizer's products include the Comirnaty COVID-19 vaccine, the Prevnar family of pneumococcal vaccines, and medicines such as Eliquis, Ibrance, Vyndaqel and Zavzaret.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.